ProstaLund AB announced that Schelin Catheter® has been approved for sale in the province of Hainan in China. With the help of the Chinese distributor, ProstaLund's Schelin Catheter® has now been approved for sale in the province. With Schelin Catheter®, the prostate can be effectively locally anesthetized in a simple and sterile way.

Schelin Catheter® has been used as standard for many years before thermotherapy treatment with ProstaLund's own method CoreTherm®. In 2022, there were world premieres for the use of Schelin Catheter® in conjunction with a variety of prostate surgeries such as water vapor therapy, green laser surgery and others. Schelin Catheter® means that most prostate surgeries can be moved from resource-intensive operating theaters to ambulatory settings and thus contribute to major savings in terms of healthcare resources, hospital beds and money.

At the same time, the patient does not need to be general anesthetized and can thus go home immediately after treatment. Last year, the company received approval for a so-called utility patent for Schelin Catheter® in China. The Chinese distributor has, together with ProstaLund, started the process for national registration for China, which is expected to take about 18-24 months to get in place.